Typhoid Fever Vaccines - Global Strategic Business Report

The global market for Typhoid Fever Vaccines was valued at US$430.6 Million in 2025 and is projected to reach US$1.3 Billion by 2032, growing at a CAGR of 16.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global 'Typhoid Fever Vaccines' Market - Key Trends & Drivers Summarized

Why Is The Global Fight Against Typhoid Gaining Unprecedented Momentum?

Over the past decade, the fight against typhoid fever has undergone a major transformation, especially due to renewed attention from global health authorities and the development of novel typhoid fever vaccines. The increasing burden of typhoid, particularly in low- and middle-income countries (LMICs), has triggered significant investments in preventive healthcare measures. According to the World Health Organization (WHO), typhoid fever affects between 11-21 million people globally each year, with approximately 128,000 to 161,000 deaths. Vaccines such as Typbar-TCV (Typhoid Conjugate Vaccine) have emerged as critical interventions due to their long-lasting immunity, applicability to younger age groups, and lower risk of adverse effects. What’s more, countries like Pakistan and Zimbabwe have rolled out mass immunization campaigns, which have demonstrated both efficacy and cost-efficiency. As water and sanitation improvements alone are insufficient in high-burden regions, governments are integrating vaccine programs into national immunization schedules. Moreover, the expanded support from organizations like Gavi, the Vaccine Alliance, is streamlining the financing and distribution of these vaccines, accelerating adoption in the regions most in need.

How Is Innovation Shaping The Efficacy And Reach Of Typhoid Fever Vaccines?

The evolution of typhoid vaccines from traditional live attenuated or inactivated types to conjugate vaccines has marked a pivotal advancement in terms of coverage, durability, and age-appropriate administration. Traditional vaccines like Ty21a and Vi polysaccharide had limitations in terms of age restriction (usually ineffective in children under 2) and shorter immunity. The new-generation Typhoid Conjugate Vaccines (TCVs), however, can be administered to children as young as 6 months and provide protection for up to 5 years or longer. This development has significant implications for pediatric immunization strategies in endemic regions. Furthermore, global clinical trials are exploring multi-pathogen conjugate vaccines that combine typhoid protection with other enteric diseases, such as paratyphoid and invasive non-typhoidal salmonella (iNTS). These innovations are particularly critical as antimicrobial resistance (AMR) continues to rise in Salmonella Typhi strains, rendering traditional antibiotic therapies less effective. As a result, preventive immunization is gaining traction as the most sustainable approach to typhoid control. Additionally, biotech firms are investing in thermostable formulations to mitigate cold-chain dependency, which remains a challenge in remote or under-resourced settings.

Can Strategic Policies And International Collaborations Bridge The Accessibility Gap?

As the global healthcare ecosystem becomes more interconnected, the role of policy frameworks and cross-border partnerships is proving vital to the proliferation of typhoid fever vaccines. The WHO's prequalification of TCVs has opened the doors for procurement by United Nations agencies, facilitating widespread implementation. Meanwhile, Gavi’s financial support for eligible countries has made vaccines affordable and accessible, particularly in sub-Saharan Africa and South Asia. These interventions are complemented by domestic policy reforms where ministries of health are incorporating typhoid vaccines into routine immunization schedules. Moreover, joint efforts among NGOs, health ministries, and international donors are focusing on strengthening surveillance systems, community awareness, and cold-chain infrastructure to ensure seamless distribution. Global initiatives such as the Coalition against Typhoid are also amplifying advocacy and fostering a data-driven approach to monitoring outbreaks and vaccine impact. Furthermore, the COVID-19 pandemic has highlighted the urgency of bolstering immunization systems, with governments increasingly recognizing the role of preventive vaccination as a tool for broader health resilience. Such a shift in perspective is driving new funding channels and accelerating regulatory approvals in historically underrepresented regions.

What’s Powering The Surge In Demand For Typhoid Vaccines Around The World?

The growth in the typhoid fever vaccines market is driven by several factors that are reshaping public health priorities and advancing immunization coverage globally. Firstly, the rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) typhoid strains has drastically limited treatment options, positioning vaccines as a primary line of defense. Secondly, a marked increase in urbanization without corresponding improvements in water and sanitation infrastructure in many LMICs has maintained high transmission rates, sustaining demand for preventive solutions. Thirdly, greater political commitment to combat enteric diseases, especially in Asia and Africa, has translated into comprehensive immunization campaigns and increased healthcare budgets. Additionally, improved diagnostic surveillance has enabled better identification of hotspots, allowing targeted vaccine deployment. From a technological standpoint, the development of pediatric-compatible, single-dose TCVs with extended efficacy has simplified immunization logistics and expanded age group eligibility. Moreover, rising health literacy and community engagement in vaccine initiatives have improved public receptivity, reducing vaccine hesitancy. Lastly, the growing presence of global and regional vaccine manufacturers has increased supply chain reliability, fostering a competitive environment that encourages innovation and price reduction - two key levers in expanding vaccine accessibility across diverse geographies.

Report Scope

The report analyzes the Typhoid Fever Vaccines market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccine, Conjugate Vaccine, Other Types); Administration Route (Oral, Injection); End-Use (Hospitals & Clinics, Specialty Centers, Other End-Uses)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Live Attenuated Vaccine segment, which is expected to reach US$629.7 Million by 2032 with a CAGR of a 17.8%. The Capsular Polysaccharide Vaccine segment is also set to grow at 17.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $117.3 Million in 2025, and China, forecasted to grow at an impressive 21.7% CAGR to reach $285.2 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Typhoid Fever Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Typhoid Fever Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Typhoid Fever Vaccines Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Bavarian Nordic A/S, Bharat Biotech International Ltd., Biological E. Limited, Bio-Med Pvt. Ltd., Cadila Healthcare Ltd. (Zydus Lifesciences) and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Typhoid Fever Vaccines market report include:

• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E. Limited
• Bio-Med Pvt. Ltd.
• Cadila Healthcare Ltd. (Zydus Lifesciences)
• Chiron Behring Vaccines Pvt. Ltd.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Haffkine Bio-Pharmaceutical Corp. Ltd.
• Incepta Vaccine Ltd.
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• PaxVax, Inc.
• Pfizer Inc.
• Prokarium Ltd.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanta Biotechnics Ltd.
• SK bioscience Co., Ltd.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.